Virgil Craig Jordan , OBE, PhD, DSc, FMedSci (born in Texas, US, UK/America together nationally) is a scientist specializing in medicines for the care and prevention of breast cancer. Currently, he is Professor of Breast Medical Oncology, and Professor of Molecular and Cellular Oncology at MD Anderson University Texas Cancer Center, Houston, Texas. Previously, he was the Scientific Director and Deputy Chief of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the nature of breast cancer prevention from tamoxifen and the scientific principles for adjuvant therapy with antihormones. Recently his work has developed into the prevention of various diseases in women with the discovery of drug groups, selective estrogen receptor modulators (SERMs). Currently, he plans to develop a new Hormone Replacement Therapy (HRT) for postmenopausal women who prevent breast cancer and do not increase the risk of breast cancer.
Raloxifene's Effect on Breast Cancer Risk in Post-Menopausal Women - Results from more randomized trials were among the top 20 papers cited in breast cancer research during 2003 and 2004..
Video V. Craig Jordan
Kehidupan awal
Born in New Braunfels, Texas, USA, Jordan moved to England with his family as a child. He went to school at the Moseley Hall Grammar School in Cheshire before attending Leeds University where he received his BSc, PhD and DSc degrees in Pharmacology.
Maps V. Craig Jordan
Research career
Jordan began work on anti-estrogen activity-structures as part of his PhD program at Leeds University. During that time, he met Arthur Walpole, the patent holder for the drug that became tamoxifen.
In September 1972, Jordan became a Visiting Scientist at Worcester Foundation for Experimental Biology, Massachusetts. While there he began to examine the idea that tamoxifen, a selective estrogen receptor modulator (SERM), can block estrogen receptors in breast tumors. Estrogen receptors in breast tumors attract estrogen which is then absorbed into cancer cells and encourages cells to divide, causing cancer to grow. Until now, the treatment for this type of breast cancer is oophorectomy.
Jordan returned to Leeds University as a Lecturer in Pharmacology between 1974 and 1979, after which he spent a year at Ludwig Institute for Cancer Research at the University of Bern, Switzerland.
In 1980, Jordan joined the University of Wisconsin-Madison where he began to see the effects of tamoxifen and other SERMs, raloxifene, on bone density and coronary systems. This is necessary because of concerns that long-term use of SERM can lead to osteoporosis and heart disease. Jordan's research shows that postmenopausal women who take these drugs do not suffer from a decrease in bone density or an increase in blood cholesterol. Raloxifene is now used in the prevention of osteoporosis. Jordan obtained a full professorship in Wisconsin in 1985, the same year his alma mater awarded him DSc awards.
In 1993, Jordan became Professor of Cancer Pharmacology at Northwestern University Medical School in Chicago, IL., And director of the Breast Cancer Research Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He was the prime holder of Diana Putri Wales Cancer Research Professor (1999-2004).
In January 2005, Jordan was Chairman Alfred G. Knudson of the Cancer Research at Fox Chase Cancer Center in Philadelphia, PA. He recently published a work showing that estrogen, given at the right time, causes the destruction of cancer cells rather than feeding their growth. Jordan is the Scientific Director of Lombardi's Comprehensive Cancer Center, Professor of Oncology and Pharmacology, Deputy Chief of the Department of Oncology, and Vincent T. Lombardi Chair of Cancer Cancer Researcher, Georgetown University, Washington, DC, before moving to Texas.
Personal life and national services
Jordan is the father of two daughters, Helen Melissa Yvonne Turner and Alexandra Katherine Louise Noel. Military Service: Captain Intelligence Corps (V) (On staff of the British Deputy Chief of Scientist (Army) (1971-75), Attach NBC Area Officer 1 US Mobilization Designer, DEA Officer Course and Police Narcotics Police Training UK (1973-78) 23 Special Air Service (1975-79) (Commanding Officer Rory Walker (1975-1978)), (Commanding Officer Tony Hunter-Choat (1978-1979)), (Director of SAS Group, Brig. Johnny Watts (1975-1979))) , RARO SAS (1979-97). SAS Regimental Association (2008-present).
Awards (select)
2012 Louis S. Goodman and Alfred Gilman Award at Receptor Pharmacology, American Society for Pharmacology and Experimental Therapeutics
2011 Gallen Prize for Clinical Breast Cancer Research, Switzerland
Penghargaan David A. Karnofsky 2008 dari American Society of Clinical Oncology
2006 American Cancer Society Award dan Ceramah dari American Society for Clinical Oncology.
2003 Kettering Prize
2002 American Cancer Society Medal of Honor for basic research.
2002 became British Royal Order Officer by Queen Elizabeth II for international breast cancer research service.
2001 Bristol-Myers Squibb Award for Extraordinary Achievement in Cancer Research.
2001 Doctor of Medicine, honoris causa from University of Leeds
1993 Cameron Prize from the University of Edinburgh
1993 ASPET Award from the American Society of Pharmacology and Experimental Therapeutics.
1993 The Gaddum Memorial Award dari British Pharmacological Society
1992 Brinker International Breast Cancer Award for Basic Science from Susan G. Komen for Healing.
Recent books
Tamoxifen-Pioneer of Medicine in Breast Cancer by Philipp Y. Maximov, Russell E. McDaniel and V. Craig Jordan (2013). Milestones in the Drug Therapy Series. Springer Basel AG, Basal, Switzerland.Top quote publication
Source of the article : Wikipedia
0 Comments